KVÄLLSSYMPOSIUM 2008 Vaccinering av hund och katt

276 S.M. Moore et al. / Biologicals 33 (2005) 269e276
Acknowledgments
The authors would like to thank the Centers for
Disease Control and Prevention and Chiron Vaccines
for donating the challenge viruses used in this study. In
addition, our appreciation is extended to Dr Iris
Stalkamp for providing phylogenetic data and sequence
comparison information and to Dr Tony Stamp and
Mal Hoover for their valuable assistance in preparing
some of the figures used in this paper.
References
[1] Lafon M, Edelman L, Bouvet JP, Lafage M, Martchatre E.
Human monoclonal antibodies specific for the rabies virus
glycoprotein and N protein. J Gen Virol 1990;71:1689e96.
[2] Smith JS, Yager PA, Baer GM. A rapid reproducible test for
determining rabies neutralizing antibody. Bull World Health
Organ 1973;48:535e41.
[3] Cliquet F, Aubert M, Sagné L. Development of a fluorescent
antibody virus neutralization test (FAVN test) for the quantitation
of rabies-neutralising antibody. J Immunol Methods
1998;212:79e87.
[4] Blancou J, Aubert MF, Cain E, Selve M, Thraenhart O,
Bruckner L. Effect of strain differences on the potency testing of
rabies vaccines in mice. J Biol Stand 1989;17(3):259e66.
[5] Ferguson M, Wachmann B, Needy C, Fitzgerald EA. The effect
of strain differences on the assay of rabies virus glycoprotein by
single radial immunodiffusion. J Biol Stand 1987;15:73e7.
[6] Smith JS. Molecular epidemiology. In: Jackson AC, Wunner WH,
editors. Rabies. 1st ed. San Diego, CA, USA: Academic Press;
2002. p. 79e111.
[7] Smith JS. Rabies serology. In: Baer GM, editor. The natural
history of rabies. 2nd ed. Boca Raton, FL, USA: CRC Press;
1991. p. 235e52.
[8] Tordo N. Characteristics and molecular biology of the rabies
virus. In: Meslin FX, Kaplan MM, Koproski H, editors.
Laboratory techniques in rabies. 4th ed. Geneva, Switzerland:
World Health Organization; 1996. p. 28e51.
[9] Maillard A, Gaudin Y. Rabies virus glycoprotein can fold in two
alternative, antigenically distinct conformations depending on
membrane-anchor type. J Gen Virol 2002;83:1465e76.
[10] Smith JS, Yager PA, Baer GM. A rapid fluorescent focus
inhibition test (RFFIT) for determining rabies virus-neutralizing
antibody. In: Meslin FX, Kaplan MM, Koproski H, editors.
Laboratory techniques in rabies. 4th ed. Geneva, Switzerland:
World Health Organization; 1996. p. 181e92.
[11] Centers for Disease Control and Prevention. Human rabies
prevention-United States, 1999: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR
Morb Mortal Wkly Rep 1999;RR-1:1e21.
[12] WHO Expert Committee on Rabies. 8th Report. Geneva,
Switzerland: World Health Organization; 1992 [WHO Technical
Report Series, No. 824].
[13] Code of Federal Regulations Title 21 Subpart A 320.1 Definitions.
Food and Drug Administration, Health and Human
Services.
[14] Briggs DJ. Public health management of humans at risk. In:
Jackson AC, Wunner WH, editors. Rabies. 1st ed. San Diego,
CA, USA: Academic Press; 2002. p. 401e28.
[15] Lodmell DL, Smith JS, Esposito JJ, Ewalt LC. Cross-protection
of mice against a global spectrum of rabies virus variants. J Virol
1995;69:4957e62.